A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Stavudine
Eligibility Criteria
Inclusion Criteria Patients must have: HIV positivity with CD4 count < 300 cells/mm3. Intolerance to or failure on approved antiretroviral therapy. Ability to provide informed consent (of parent or guardian if appropriate). NOTE: Incarcerated persons may be eligible to participate. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Grade 2 or worse disease-related peripheral neuropathy. Unresolved drug-related peripheral neuropathy of any severity that is attributable to other nucleoside analogs (AZT, ddC, ddI). Malignancy likely to require systemic chemotherapy with myelosuppressive or neurotoxic drugs in the first 3 months of stavudine treatment. Pregnancy (physicians of pregnant patients may contact Bristol-Myers to determine eligibility for stavudine therapy in another protocol). Strongly discouraged: AZT, ddI, ddC, and other antiretroviral agents.
Sites / Locations
- Bristol - Myers Squibb Co